Cedarburg Hauser Pharmaceuticals has announced the addition of controlled substance capabilities at its Denver, CO facility. Both of Cedarburg Hauser's facilities, in Colorado and Wisconsin, now hold DEA registrations allowing for the production and analysis of schedule II-V controlled substances.

The kilo-lab manufacturing suites and analytical laboratories at the Denver location are ideal for the development of small molecule APIs, particularly those with unique manufacturing challenges such as potent compounds, controlled substances, and small molecule conjugates.

Cedarburg Hauser specializes in the development and manufacturing of small molecule APIs. We leverage a talented group of scientists and supporting-staff, as well as a centralized approach to project management, to ensure on-time and on-budget completion of projects involving the development, scale-up, and manufacturing of complex APIs.